Growth hormone releasing peptide (GHS-R agonist)
Growth hormone releasing hexapeptide
An early GH secretagogue peptide notable for strong GH release and significant appetite stimulation.
- Evidence:
- Moderate human evidence
- Status:
- Not FDA-approved
- Reviewed:
- 2026-08-03
Also known as: Growth hormone releasing hexapeptide
What is Growth hormone releasing hexapeptide?
An early GH secretagogue peptide notable for strong GH release and significant appetite stimulation.
This profile is educational. It organizes publicly discussed research context for Growth hormone releasing hexapeptide and related naming aliases — it is not a treatment guide.
Proposed mechanism
GHS-R agonism with pronounced ghrelin-mimetic appetite effects via hypothalamic feeding circuits.
Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.
Current research notes
Human evidence grade: Moderate human evidence
Preclinical evidence grade: Strong human evidence
GHRP-6 was among the first synthetic GHRPs characterized. Robust GH release in humans but significant hunger side effect limits therapeutic interest. Extensively used as research tool. WADA prohibited.
Key uncertainties
- Therapeutic niche vs newer selective GHRPs
Research areas being studied
- GH axis research
- Appetite regulation
- Cachexia research
Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.
Safety & side-effect notes
Reported or discussed adverse effects
- Severe hunger
- Water retention
- Tiredness after GH peak
Additional risks & considerations
- Significant appetite increase
- Cortisol/prolactin effects
- WADA prohibited
Regulatory status
Not FDA-approved
Regulatory framing here is educational and can lag policy changes. Check official sources for current status.
Frequently asked questions
What is Growth hormone releasing hexapeptide?
An early GH secretagogue peptide notable for strong GH release and significant appetite stimulation.
How does Growth hormone releasing hexapeptide work (proposed mechanism)?
GHS-R agonism with pronounced ghrelin-mimetic appetite effects via hypothalamic feeding circuits.
What is Growth hormone releasing hexapeptide being researched for?
Growth hormone releasing hexapeptide has been discussed in research contexts including: GH axis research, Appetite regulation, Cachexia research.
What does current evidence say about Growth hormone releasing hexapeptide?
Moderate human evidence. GHRP-6 was among the first synthetic GHRPs characterized. Robust GH release in humans but significant hunger side effect limits therapeutic interest. Extensively used as research tool. WADA prohibited.
What safety considerations are noted for Growth hormone releasing hexapeptide?
Reported or discussed considerations include: Severe hunger; Water retention; Tiredness after GH peak; Significant appetite increase; Cortisol/prolactin effects; WADA prohibited. This is educational information, not medical advice.
References & sources
- Ghigo E et al. (1997). GHRP-6 and the ghrelin receptor — J Clin Endocrinol Metab. Evidence type: human.
Prefer interactive tools? Open the PepGuide library entry for Growth hormone releasing hexapeptide or ask PepGuide AI.
Educational and research information only. PepGuide does not sell or prescribe peptides, diagnose conditions, or provide personalized medical advice. Evidence summaries may include early-stage, animal, or limited human research — none of that is a substitute for primary literature or clinician guidance.